- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02406053
Oxidative Damage and Antioxidant Mechanisms in COPD
Evaluation of Oxidative Damage and Antioxidant Mechanisms in COPD, Lung Cancer, and Obstructive Sleep Apnea Syndrome
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Introduction Lung is a particularly important organ because of its interface with the environment. The environmental pollutants and endogenous reactive oxygen metabolites from inflammatory cells exert substantial pathological effects on the lung cells [1]. Oxidative stress (OS) is a major factor that plays a significant role in lung cancer (LC) [2], chronic obstructive pulmonary disease (COPD) [3] and obstructive sleep apnea syndrome (OSAS) [4, 5]. The current evidence suggests that OS takes part in the mechanisms involved in initiation, promotion and progression of respiratory diseases. The major exposures that cause OS can be summarized as smoking, and ambient air pollution that contains particulate matter smaller than aerodynamic diameter of 2.5 µm [6-8]. Epidemiological and clinical studies showed that the overall outcome of pulmonary OS is increased mortality due to increased incidence of respiratory diseases [9].
In OSAS, an episodic hypoxia-reoxygenation cycle occurs during intermittent nocturnal hypoxias that causes the production of reactive oxygen metabolites [10]. These metabolites are responsible for the activation of inflammatory cells in OSAS [11, 12], and their increased levels eventually cause ischemia-reperfusion injury [13], and cellular and DNA damage [14, 15]. The latter, is also a significant contributor of LC progression. The DNA damage in the presence of reactive oxygen metabolites yields carcinogenesis by several mechanisms. Some of them are single or double-stranded DNA breaks, and modifications in purines or pyrimidines. Nevertheless, OS is not the only susceptible factor for carcinogenesis, there are also many other pathological mechanisms contributing to cancer development, such as reactive nitrogen species, and involvement of mitochondrial DNA mutations [16] in inflammatory conditions. Previous studies reported that LC occurs two-to-five times higher in patients with moderate-to-severe COPD [17, 18]. OS is also the main etiological factor of COPD, which is particularly important in the acute exacerbations of the disease [19]. The parenchymal damage in COPD includes some mechanisms such as chronic inflammation, OS, deteriorations in the balance of protease and antiprotease activities, and apoptosis [20]. The major etiological factor that suspected to play role in the progression of LC in COPD is reported as chronic inflammation, which causes induction of several interleukins and cyclooxygenase-2 activity. The inflammatory micro-environment is a potential medium for contributing the neoproliferative process, which interacts with regulatory mechanism such as apoptosis and angiogenesis [21].
Some biomarkers are available for evaluating the OS in the living organisms [22]. Some of these biomarkers are malondialdehyde (MDA), 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-OHdG), and coenzyme Q10 (CoQ10). Each of these biomarkers is involved in oxidative processes. MDA is a by-product of polyunsaturated fatty acid peroxidation [23]. Lipid peroxidation is the oxidation reactions between reactive oxygen metabolites and polyunsaturated fatty acids, which eventually causes changes in the structure and permeability of lung membrane [24]. The second biomarker, 8-OHdG, is primarily involved in DNA damage. The mechanism for this damage is the guanine: cytosine to adenine: thymine transversion on DNA replication [25], which induces microsatellite instability, and abnormal apoptosis or necrosis [26]. The third biomarker is CoQ10, which is also a mediator of lipid peroxidation, and an essential cofactor in the electron-transport chain (ETC). It is also a lipophilic antioxidant component of the lipid membranes [27]. In this study.
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Malondialdehyde (MDA), 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-OHdG), and coenzyme Q10 (CoQ10) levels were evaluated in the blood samples of patients with COPD, LC, and OSAS by high-pressure liquid chromatography method.
Exclusion Criteria:
- The diagnosis of lung cancer was based on the analysis of biopsy or cytologic specimens obtained by bronchoscopic examination, transthoracic biopsy or surgery. The patients Who hadn't have chemo or/and radiotherapy were included to the study.
- The exclusion criteria for COPD, OSAS and lung cancer were the presence of the following: history of cardiovascular disease, hypertension, diabetes mellitus, inflammatory or infectious.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
HC
Healthy controls
|
the oxidative damage in these diseases by evaluating the oxidative and antioxidant biomarkers.
|
COPD
Chronic obstructive pulmonary disease
|
the oxidative damage in these diseases by evaluating the oxidative and antioxidant biomarkers.
|
OSAS
Obstructive sleep apnea syndrome
|
the oxidative damage in these diseases by evaluating the oxidative and antioxidant biomarkers.
|
LC
Lung cancer
|
the oxidative damage in these diseases by evaluating the oxidative and antioxidant biomarkers.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Oxidative damage by evaluating the oxidative and antioxidant biomarkers
Time Frame: 4 months
|
This study aimed to evaluate the oxidative damage in these diseases by evaluating the oxidative and antioxidant biomarkers
|
4 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: AYSEL SUNNETCIOGLU, Phd, Yuzuncu Yıl University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- YYU-016
- YYU-2015-66 (Other Identifier: YUZUNCU YIL UNIVERSITY)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Diseases
-
Assistance Publique - Hôpitaux de ParisCompletedRespiratory Diseases | Chronic and Acute Respiratory FailureFrance
-
University of Wisconsin, MadisonCompletedRespiratory Failure | Pediatric Respiratory DiseasesUnited States
-
SOS Oxygene MediterraneeRecruitingExercise | Chronic Respiratory DiseaseFrance
-
Poitiers University HospitalRecruitingAcute Respiratory Failure | Hypoxemic Respiratory FailureFrance
-
St. Jude Children's Research HospitalCompletedRespiratory Failure | Respiratory DiseaseUnited States
-
Triclinium Clinical Development Middle East and...ezz medical IndustriesNot yet recruitingRespiratory Failure | Respiratory DiseaseEgypt
-
Centro Universitário Augusto MottaUniversidade Federal do Rio de JaneiroCompletedRespiratory Failure | Respiratory DisordersBrazil
-
University of Colorado, DenverBiofireCompletedAcute Respiratory Infection | Lower Respiratory Tract Illness | Respiratory Pathogens | Upper Respiratory Tract IllnessUnited States
-
Russian Federation of Anesthesiologists and ReanimatologistsRecruitingRespiratory Failure | Respiratory Disease | SurveyRussian Federation
-
Basque Health ServiceActive, not recruitingAcute Respiratory FailureSpain
Clinical Trials on oxidative and antioxidant biomarkers
-
University of PortsmouthPortsmouth Hospitals NHS TrustNot yet recruitingCompartment Syndrome Nontraumatic Lower ExtremityUnited Kingdom
-
Grigore T. Popa University of Medicine and PharmacyCardiovascular Diseases Institute IASI, RomaniaUnknownOxidative Stress | STEMI | Left Ventricular Dysfunction | Oxidative Stress Induction | Primary PCI | hFABP | BCMRomania
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Chulalongkorn UniversityUnknownLow ResponderThailand
-
Ataturk Training and Research HospitalCompletedOxidative Stress | Waterpipe Smoking
-
Calla IVF CenterRecruitingPregnancy | Oxidative Stress | Fertility Disorders | IVFRomania
-
University Hospital, Clermont-FerrandUniversity Hospital, Limoges; Institut National de Recherche pour l'Agriculture...Unknown
-
Merve Erkmen AlmazKırıkkale UniversityCompletedDental Caries | Oxidative Stress | Passive Smoking
-
Clinique OvoFerring PharmaceuticalsRecruitingFertility PreservationCanada
-
University of FlorenceCareggi Hospital; University of Milano Bicocca; Fondazione C.N.R./Regione Toscana...RecruitingBladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma | Urothelial Neoplasm | Urothelial Carcinoma in SituItaly